Anete is a Full Professor of Internal Medicine at the Federal University of Rio de Janeiro. She is a senior investigator dedicated to tuberculosis (TB) elimination, coordinator of the clinical research session (and former president) at the Brazilian TB Network (Rede-TB). She was the PI in Brazil of several clinical trials on TB infection (TBI) detection and treatment, in collaboration with the McGill International Centre. Among them, she led a large operational study, initially funded by Stop Tb Partnership and subsequently funded by the Brazilian Ministry of Health, the Expand TPT. The program was based on lessons learned from the ACT-4 clinical trial and conceived and analyzed in collaboration with the McGill TB International Centre leading researchers Prof. Dick Menzies and Dr. Jonathon Campbell. During the ExpandTPT intervention, the prescription of TPT to contacts increased monthly 1.5% more in intervention than in control cities when compared to pre-intervention trends, which translated into a 30% increase of TPT prescriptions in the country.
Current research projects:
She is currently the PI in Brazil of the multicentre TB Drugs/TB Vaccines: Critical Pathway Mapping & Analysis study conducted by Prof. Madhukar Pai, also a leading researcher from the MTIC. The study aims to support the introduction of novel TB vaccines (e.g. M72/AS01E-4) and drug regimens (e.g. pan-TB), by understanding and creating country-specific critical paths and roadmaps in high priority African, Asian, and South American countries for the initial introduction, regulatory approval, and NTP/MOH adoption of new vaccines and drug combinations.
She also collaborates with the Vanderbilt University in the Regional Prospective Observational Research in Tuberculosis - Brazil (RePORT-Brazil) project, led by Prof. Timothy Sterling. She acts as a reviewer of post-doctoral and fellowship grantees’ projects in the RePORT-Brazil Advanced Career Training (ReACT) program. The RePORT International is a partnership funded by the USA NIH, which prospectively collects epidemiological and clinical data as well as biological specimens from cohorts of people with TB and their contacts.
Other ongoing and recent projects focus on efficacy, effectiveness, and cost-effectiveness of new regimens and diagnostics for TBI. She has supervised 30 graduate and 68 undergraduate students and published in most aspects that maintain TB as one of the leading causes of death in the world: poor prevention of the disease through preventive treatment of LTBI, drug-resistant TB, HIV-associated TB, primary care health system strengthening and poverty as a social determinant of TB.
Email: atrajman [at] gmail.com
